What is the main difference between MK-677 and ipamorelin?

Both have growth hormone secretagogue activity, but MK-677 is a nonpeptide studied orally; ipamorelin is a pentapeptide with preclinical selectivity work, a human GH-response study and a separate randomized postoperative-ileus trial.

Did the human ipamorelin trial show clinical benefit?

In a randomized Phase 2 study after bowel resection, the primary time-to-tolerated-meal result and secondary efficacy analyses were not significantly different from placebo. This gastrointestinal endpoint does not establish body-composition benefit.

Did MK-677 improve strength or function?

Its 65-person older-adult trial found more fat-free mass but no significant strength or function improvement; it was not powered to rule out a functional effect.

Does ipamorelin have a proven safer metabolic profile?

No comparative human trial cited here establishes a safer glucose, appetite or long-term profile than MK-677.

Is either FDA approved?

No FDA-approved ibutamoren or ipamorelin product is identified in the cited official reviews. Ibutamoren development as LUM-201 does not mean approval.

MK-677 vs Ipamorelin: Human Evidence and Limits

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Mechanism is not an outcome

MK-677 (ibutamoren) is an oral, nonpeptide ghrelin-receptor agonist. Ipamorelin is a pentapeptide growth hormone secretagogue. The original ipamorelin selectivity study used rat pituitary cells and animal models, including swine; those results cannot establish a cleaner clinical safety profile or human muscle benefit. FDA ibutamoren review; Raun et al., PMID 9849822.

Ipamorelin also has human hormone-response data. A randomized, placebo-controlled pharmacokinetic/pharmacodynamic study enrolled 48 healthy men and measured plasma ipamorelin and GH after intravenous infusion. It characterized GH release, not treatment of growth hormone deficiency, body composition or functional benefit. Gobburu et al., PMID 10496658; FDA ipamorelin assessment.

Question	MK-677	Ipamorelin
Chemistry	Nonpeptide	Peptide
Evidence cited here	Randomized human trials across distinct populations	Preclinical selectivity work, a randomized human GH-response study and a randomized Phase 2 postoperative-ileus trial
Functional outcome	No significant strength/function improvement detected in one older-adult trial; trial underpowered for this endpoint	Postoperative meal-tolerance endpoint did not improve significantly; muscle/function benefit was not tested
FDA approval	No approved ibutamoren product	No approved ipamorelin product identified

The MK-677 older-adult trial included 65 healthy adults. GH, IGF-1 and fat-free mass increased, but abdominal visceral fat, strength and function did not improve significantly. The trial’s size and duration were insufficient to assess functional endpoints definitively. Fasting glucose increased and insulin sensitivity decreased. These are population-specific results, not a direct comparison with ipamorelin. Nass et al., PMID 18981485.

Ipamorelin was also tested in a randomized, double-blind Phase 2 human trial for postoperative ileus after bowel resection (NCT00672074). Of 117 enrolled patients, 114 were included in the safety and modified intent-to-treat populations. Median time to tolerating a solid meal was 25.3 hours with intravenous ipamorelin and 32.6 hours with placebo (p = 0.15); the primary and secondary efficacy analyses found no significant difference. This small proof-of-concept trial assessed gastrointestinal recovery, not body composition, strength or anti-aging benefit. Beck et al., PMID 25331030.

FDA’s 2024 assessment identifies ibutamoren/MK-677/LUM-201 as the same molecule and no FDA-approved product. FDA separately states that ipamorelin is not a component of an approved drug. The earlier Merck ibutamoren program ended, yet pediatric LUM-201 development continued; NCT06948214 was marked recruiting in the September 29, 2026 official registry archive. These facts do not establish approval or efficacy for aging, muscle gain or recovery. FDA ibutamoren assessment; FDA ipamorelin assessment.

There is no cited head-to-head trial supporting a clinical winner or combination. This page does not make a use recommendation.

MK-677 vs Ipamorelin

MK-677

Ipamorelin

Mechanism is not an outcome

View Full Dossiers

Stay Updated on Peptide Comparisons